Agios Pharmaceuticals (NASDAQ:AGIO) Trading 5.2% Higher - Still a Buy?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report)'s share price was up 5.2% during mid-day trading on Monday . The stock traded as high as $40.99 and last traded at $40.99. Approximately 84,013 shares changed hands during trading, a decline of 88% from the average daily volume of 714,662 shares. The stock had previously closed at $38.97.

Analyst Upgrades and Downgrades

AGIO has been the topic of a number of analyst reports. Leerink Partnrs lowered Agios Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Friday, September 27th. Raymond James reiterated an "outperform" rating and issued a $51.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Scotiabank increased their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a "sector outperform" rating in a report on Monday, December 9th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Finally, Leerink Partners downgraded Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and cut their target price for the company from $60.00 to $56.00 in a research note on Friday, September 27th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Agios Pharmaceuticals presently has an average rating of "Hold" and a consensus target price of $56.33.

Agios Pharmaceuticals Stock Performance

The firm has a market capitalization of $2.43 billion, a P/E ratio of 3.73 and a beta of 0.80. The firm has a 50 day moving average price of $50.02 and a two-hundred day moving average price of $46.76.

Insider Transactions at Agios Pharmaceuticals

In related news, CFO Cecilia Jones sold 2,542 shares of the firm's stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the transaction, the chief financial officer now owns 20,158 shares of the company's stock, valued at approximately $988,346.74. This trade represents a 11.20 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.93% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several hedge funds have recently bought and sold shares of the business. Caxton Associates LP grew its stake in Agios Pharmaceuticals by 0.7% in the 2nd quarter. Caxton Associates LP now owns 37,453 shares of the biopharmaceutical company's stock valued at $1,615,000 after buying an additional 264 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Agios Pharmaceuticals by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company's stock worth $94,000 after purchasing an additional 363 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Agios Pharmaceuticals by 6.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,132 shares of the biopharmaceutical company's stock valued at $539,000 after purchasing an additional 688 shares during the period. Acadian Asset Management LLC acquired a new stake in Agios Pharmaceuticals in the 2nd quarter valued at approximately $37,000. Finally, Quest Partners LLC bought a new position in Agios Pharmaceuticals in the 2nd quarter worth approximately $40,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.